Immunotherapy: New directions for tumour therapy

Buckland, Jenny
July 2003
Nature Reviews Immunology;Jul2003, Vol. 3 Issue 7, p513
Academic Journal
Presents the result of a study on the treatment of tumors by using a bone marrow transplantation-based strategy in which hematopoietic stem cells are transduced with genes. Development of dendritic cell-based anti-tumor vaccines; Methodology of the study; Details of the success of the strategy.


Related Articles

  • Hematopoietic stem cell transplantation activity in Europe 1999. Gratwohl, A; Passweg, J; Baldomero, H; Urbano-Ispizua, A // Bone Marrow Transplantation;5/1/2001, Vol. 27 Issue 9, p899 

    This survey on transplantation of hematopoietic stem cells from blood or bone marrow in Europe, the 10th in a series, reports the numbers of transplants performed in 1999 and concentrates on changes in indications and donor types. Members of the European Group for Blood and Marrow...

  • Immunotherapy: New directions for tumour therapy. Buckland, Jenny // Nature Reviews Cancer;Jul2003, Vol. 3 Issue 7, p472 

    Informs that a bone marrow transplant (BMT)-based strategy for treating established tumors in which hematopoietic stem cells (HSC) are transduced with genes that encode tumor antigens. Limitations of dendritic cell-based antitumor vaccines for treatment of tumors; Methodology adopted for...

  • Immunotherapy of established tumors using bone marrow transplantation with antigen gene-modified hematopoietic stem cells. Cui, Yan; Kelleher, Erin; Straley, Erin; Fuchs, Ephraim; Gorski, Kevin; Levitsky, Hyam; Borrello, Ivan; Civin, Curt I; Schoenberger, Stephen P; Cheng, Linzhao; Pardoll, Drew M; Whartenby, Katharine A // Nature Medicine;Jul2003, Vol. 9 Issue 7, p952 

    A major focus of cancer immunotherapy is to develop strategies to induce T-cell responses through presentation of tumor antigens by dendritic cells (DCs). Current vaccines are limited in their ability to efficiently transfer antigens to DCs in vivo. Ex vivo—generated DCs can be...

  • Fludarabine/i.v. BU conditioning regimen: myeloablative, reduced intensity or both? Chunduri, S.; Dobogai, L. C.; Peace, D.; Saunthararajah, Y.; Quigley, J.; Chen, Y.-H.; Mahmud, N.; Hurter, E.; Beri, R.; Rondelli, D. // Bone Marrow Transplantation;Jun2008, Vol. 41 Issue 11, p935 

    In this study, we utilized a conditioning regimen with fludarabine and myeloablative dose i.v. BU (12.8 mg/kg) (FluBU) in 36 adult patients (median age: 44 years, range: 18�61) with myeloid or lymphoid malignancies at standard risk (n=10) or high risk of relapse (n=26), who received an...

  • Comorbidity and beyond: pre-transplant clinical assessment. Artz, A. S. // Bone Marrow Transplantation;Sep2005, Vol. 36 Issue 6, p473 

    Investigates the use of comorbidity scales that provide relative weights to nondisease-related medical conditions as predictors of hematopoietic stem cell transplantation outcomes. Importance of pre-transplant comorbidity assessment; Efficacy of this method compared to single organ comorbidity...

  • Comorbidity indices in hematopoietic stem cell transplantation: a new report card. Alamo, J.; Shahjahan, M.; Lazarus, H. M.; de Lima, M.; Giralt, S. A. // Bone Marrow Transplantation;Sep2005, Vol. 36 Issue 6, p475 

    Summary:Comorbid conditions have not been studied systematically for impact upon patient outcome in the setting of hematopoietic stem cell transplantation (HSCT). Patients formerly excluded from myeloablative transplant due to comorbid illnesses now receive reduced-intensity conditioning...

  • Prediction of duration and success rate of unrelated hematopoietic stem cell donor searches based on the patient's HLA-DRB1 allele and DRB1-DQB1 haplotype frequencies. Hirv, K.; Bloch, K.; Fischer, M.; Einsiedler, B.; Schrezenmeier, H.; Mytilineos, J. // Bone Marrow Transplantation;Oct2009, Vol. 44 Issue 7, p433 

    Rapid identification of a matched unrelated donor is essential for patients in need of hematopoietic SCT. We carried out a retrospective evaluation of 549 unrelated donor searches (UDSs), which were completed in 2005 for 23 German transplant centers. On the basis of the patient's HLA-DRB1 allele...

  • IL-4-producing CD8+ T cells may be an immunological hallmark of chronic GVHD. Nakamura, K.; Amakawa, R.; Takebayashi, M.; Son, Y.; Miyaji, M.; Tajima, K.; Nakai, K.; Ito, T.; Matsumoto, N.; Zen, K.; Kishimoto, Y.; Fukuhara, S. // Bone Marrow Transplantation;Oct2005, Vol. 36 Issue 7, p639 

    Summary:Chronic graft-versus-host disease (cGVHD) occurs in approximately 60–80% of those who survive over 100 days after allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, the pathophysiology of cGVHD is poorly understood. To gain more insight into the immunological...

  • Biology of human bone marrow stem cells. Bonnet, D. // Clinical & Experimental Medicine;Sep2003, Vol. 3 Issue 3, p140 

    The bone marrow is constituted of two separate and distinct stem cells. The hematopoietic stem cells (HSC) are responsible for the production and maintenance of all the mature blood cells. The mesenchymal stem cells constituted the bone marrow stroma. In this report we review our current...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics